Nektar announces positive phase 2 data from first stage of NKTR-102 study in women with platinum-resistant ovarian cancer
Wednesday, March 10, 2010 18:00 IST San Carlos, California
Nektar Therapeutics announced preliminary progression-free survival data from the first stage of a two-stage phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer.
